Effect of the Food Supplement TOTUM-070 on Lipid Metabolism
- Conditions
- Hypercholesterolemia
- Interventions
- Dietary Supplement: PLACEBODietary Supplement: TOTUM-070
- Registration Number
- NCT06243484
- Lead Sponsor
- Valbiotis
- Brief Summary
This clinical trial is to confirm the effects of TOTUM-070, a mix of 5 plants extracts, consumed at the daily regimen of two times per day, on fasting blood LDL cholesterol concentrations in moderately hypercholesterolemic subjects after 12 weeks of consumption (V3).
- Detailed Description
The main objective is to confirm the efficacy of a 4.995g/day dose of TOTUM-070 versus placebo on fasting blood LDL cholesterol level (Ultracentrifugation (UC) method) in moderately hypercholesterolemic subjects following 12 weeks of consumption (V3).
The proposed double-blinded, placebo-controlled, clinical study will provide further insight into the safety and efficacy of TOTUM-070 at the same dose (4.995g/day) on a shorter supplementation period (3 months) than the previous one (6 months), as well as assess the effect after the follow-up period without product intake.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 180
- I1. From 18 to 70 years (including ranges);
- I2. BMI of ≥18.5 and ≤35 kg/m²;
- I3. Moderately hypercholesterolemic subject without any clinical symptoms of hypercholesterolemia (xanthoma, recurrent chest and/or leg pain...) and not requiring immediate pharmacological lipid-lowering treatment;
- I4. Weight stable within ± 5% in the last three months before V0;
- I5. SCORE2 - SCORE2-OP (Older Persons) Cardiovascular Risk Chart
Main
- E1. Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal dysfunction or other metabolic disorder needing a dose adjustment in drug intervention according to the professional recommendations;
- E2. Suffering from an uncontrolled arterial hypertension;
- E3. With a history of ischemic cardiovascular event;
- E4. Having undergone recent surgical procedure in the past 6 months before V0 or planned in the 5 months to come;
- E5. History of bariatric surgery;
- E6. Suffering from a severe chronic disease;
- E7. For women: ongoing pregnancy (as evidenced by a positive test for β-Human Chorionic Gonadotropin, i.e. > 5 mUI/mL, realized at V0) or breastfeeding or finished since less than 6 months before V0 or intending to become pregnant within 5 months ahead;
- E8. Under cholesterol and/or lipid-lowering treatment or stopped less than 3 months before the inclusion visit V0;
- E9. Under medication which could affect blood lipid parameters or stopped less than 3 months before the inclusion visit V0 (antihypertensive stable long-term treatment tolerated);
- E10. Consuming more than 3 standard drinks daily of alcoholic beverage for men or 2 standard drinks daily for women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PLACEBO PLACEBO The placebo comparator arm will be supplemented with a placebo twice a day TOTUM-070 TOTUM-070 The experimental arm will be supplemented with TOTUM-070 twice a day
- Primary Outcome Measures
Name Time Method Evolution of fasting blood LDL cholesterol level Baseline (V1) and End of consumption after 12 weeks (V3) Fasting blood LDL cholesterol level by Ultracentrifugation method
- Secondary Outcome Measures
Name Time Method Evolution of Lipid profile Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Triglycerides, Total-cholesterol, HDL-C, non-HDL-C, LDL-C, Free Fatty Acids, Apo-A1 and Apo-B, Apo-B/Apo-A1 ratio, Apo-C3
Evolution of Lipid homeostasis indices Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Atherogenic index (ratio of triglycérides and HDL-C), atherogenic coefficient (ratio of total-cholesterol and HDL-C), cardiac risk ratio 1 (ratio of total-cholesterol and HDL-C), cardiac risk ratio 2 (ratio of LDL-C and HDL-C) (note that all these measures are unitless ratios)
Evolution of fasting blood LDL cholesterol level Baseline (V1), Following 6 weeks of consumption (V2) and 6 weeks after the end of consumption (V4) Fasting blood LDL cholesterol level by Ultracentrifugation method
Evolution of Low grade inflammation Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Fasting blood hsCRP, Interleukin-6
Evolution of body weight Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Body weight (BW) in kg
Evolution of body mass index Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Body mass index (BMI) in kg/m2
Evolution of fasting glycemia Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Fasting Glycemia (in mg/dL)
Evolution of waist circumference Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Waist circumference (WC) in cm
Evolution of hip circumference Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Hip circumference (HC) in cm
Evolution of waist to hip ratio Baseline (V1), Following 6 weeks of consumption (V2), at the end of consumption after 12 weeks (V3) and 6 weeks after the end of consumption (V4) Waist to hip ratio (WHR)
Trial Locations
- Locations (1)
Biotesys
🇩🇪Esslingen, Germany